Calluna Pharma Completes CAL101 Phase 2 Enrollment for Idiopathic Pulmonary Fibrosis Treatment

Key Takeaways

• Calluna Pharma completed enrollment of 161 patients in Phase 2 AURORA study for CAL101, more than six months ahead of schedule
• CAL101 targets S100A4, a novel upstream pathway in fibrotic disease, potentially offering new treatment approach for IPF patients
• Topline results expected in Q1 2027, with the drug aiming to preserve lung function in idiopathic pulmonary fibrosis patients

---

OSLO, Norway & BOSTON — Calluna Pharma announced the completion of patient enrollment in its Phase 2 AURORA clinical study evaluating CAL101 for the treatment of idiopathic pulmonary fibrosis (IPF). The study enrolled 161 patients, reaching full enrollment more than six months ahead of the original timeline.

Novel Mechanism of Action

CAL101 represents a potentially groundbreaking approach to IPF treatment as a monoclonal antibody targeting S100A4, a novel upstream pathway implicated in fibrotic disease progression. This mechanism differs from current IPF therapies by addressing the disease process at an earlier stage in the fibrotic cascade.

The accelerated enrollment demonstrates strong physician and patient interest in novel IPF treatments, reflecting the significant unmet medical need in this progressive lung disease that affects approximately 100,000 Americans.

IntelligenceRegulatory Impact▾

NMPA, PMDA, and TGA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Market Implications

Idiopathic pulmonary fibrosis remains a devastating diagnosis with limited treatment options. Current approved therapies, including pirfenidone and nintedanib, slow disease progression but do not halt or reverse the fibrotic process. CAL101’s upstream targeting approach could potentially offer superior efficacy in preserving lung function.

The ahead-of-schedule enrollment suggests robust investigator enthusiasm and may indicate favorable regulatory discussions. Successful Phase 2 results could position Calluna Pharma as a significant player in the IPF treatment landscape, currently dominated by Roche’s Esbriet and Boehringer Ingelheim’s Ofev.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Timeline and Next Steps

With enrollment complete, the AURORA study will continue monitoring patients to assess CAL101’s efficacy in preserving lung function and safety profile. Topline data is expected in the first quarter of 2027, which will determine whether the compound advances to Phase 3 development.

The study’s primary endpoint focuses on lung function preservation, measured by forced vital capacity (FVC), a key indicator of disease progression in IPF patients. Secondary endpoints likely include quality of life measures and safety assessments.

---

Frequently Asked Questions

What makes CAL101 different from existing IPF treatments?

CAL101 targets S100A4, a novel upstream pathway in fibrotic disease, potentially addressing IPF at an earlier stage in disease progression compared to current therapies like pirfenidone and nintedanib.

When will CAL101 be available to patients?

CAL101 is currently in Phase 2 trials with results expected Q1 2027. If successful, Phase 3 trials would follow, meaning potential availability is likely several years away pending regulatory approval.

How significant is completing enrollment ahead of schedule?

Early enrollment completion indicates strong physician and patient interest, suggests the study design is feasible, and may reflect positive early safety signals, though it doesn’t guarantee efficacy.

Related coverage

• Orion Pharma's ODM-212 Shows Favorable Safety in Phase 1/2 TEADES Trial for Advanced Solid Tumours
• Risen Pharma Initiates Phase 2 Trial for RP902 in Alzheimer's
• BeOne Medicines' HERIZON-GEA Phase 3 Data in NEJM: A Deep Dive for Pharma BD and Investors